• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

(3H)长春新碱在大鼠和犬体内的分布与排泄

Distribution and excretion of (3H)vincristine in the rat and the dog.

作者信息

Castle M C, Margileth D A, Oliverio V T

出版信息

Cancer Res. 1976 Oct;36(10):3684-9.

PMID:953993
Abstract

The distribution and excretion of tritiated vincristine were studies in the rat and the dog. Biphasic curves for the disappearance of the drug from blood were found in both species, with an initial half-life of approximately 15 min and a secondary half-life of approximately 75 min. Tissue levels were high in 1 hr in the rat and declined rapidly, except in the brain where very low levels of drug were found at all times. The bile was found to be the major route of excretion. The peak rate of excretion in bile was found to occur earlier in the rat (10 min) than in the dog (60 min). Rats given a higher dose of vincristine (1.0 mg/kg) excreted a larger percentage of the dose in the bile than rats given a lower dose (0.1 mg/kg). In rats given a low dose of vincristine (0.1 mg/kg), more than 85% of the drug was excreted in the feces and the urine over 72 hr. Less than 10% of the total radioactivity in the bile and urine was metabolites whereas, in the plasma, metabolites accounted for 40% of the total radioactivity.

摘要

研究了氚标记长春新碱在大鼠和犬体内的分布与排泄情况。在这两种动物中均发现药物从血液中消失呈现双相曲线,初始半衰期约为15分钟,次级半衰期约为75分钟。大鼠在1小时时组织水平较高,随后迅速下降,但脑部除外,在脑部任何时候药物水平都非常低。胆汁是主要排泄途径。发现胆汁中排泄的峰值速率在大鼠中(10分钟)比在犬中(60分钟)出现得更早。给予高剂量长春新碱(1.0毫克/千克)的大鼠比给予低剂量(0.1毫克/千克)的大鼠在胆汁中排泄的剂量百分比更高。给予低剂量长春新碱(0.1毫克/千克)的大鼠,超过85%的药物在72小时内通过粪便和尿液排泄。胆汁和尿液中总放射性的不到10%是代谢产物,而在血浆中,代谢产物占总放射性的40%。

相似文献

1
Distribution and excretion of (3H)vincristine in the rat and the dog.(3H)长春新碱在大鼠和犬体内的分布与排泄
Cancer Res. 1976 Oct;36(10):3684-9.
2
Distribution and metabolism of vincristine in mice, rats, dogs, and monkeys.长春新碱在小鼠、大鼠、狗和猴子体内的分布与代谢。
Cancer Treat Rep. 1977 Oct;61(7):1269-77.
3
Metabolism of labetalol by animals and man.拉贝洛尔在动物和人体内的代谢。
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):695-710.
4
Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.大鼠、犬和猴单次口服给予[羰基-14C]枸橼酸莫沙必利后的吸收、分布及排泄情况。
Arzneimittelforschung. 1993 Oct;43(10):1084-94.
5
Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.酮色林在大鼠、兔和犬体内的药代动力学及组织分布
Arzneimittelforschung. 1988 Jun;38(6):775-84.
6
Biliary excretion of colchicine.秋水仙碱的胆汁排泄
J Pharmacol Exp Ther. 1975 Mar;192(3):605-17.
7
Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.新型抗癌药物酒石酸长春瑞滨在小鼠、大鼠和犬静脉注射后的处置情况。
Arzneimittelforschung. 1993 Dec;43(12):1367-77.
8
The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans.(S)-2-(3-叔丁基氨基-2-羟基丙氧基)-3-氰基吡啶在大鼠、狗和人体内的代谢情况。
Drug Metab Dispos. 1980 May-Jun;8(3):163-7.
9
Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.新型降胆固醇化合物S-8921在大鼠和犬体内的处置与代谢
Arzneimittelforschung. 1998 Oct;48(10):995-1006.
10
The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.罗非昔布(一种强效且选择性的环氧化酶-2抑制剂)在大鼠和犬体内的吸收、分布、代谢及排泄情况。
Drug Metab Dispos. 2000 Oct;28(10):1244-54.

引用本文的文献

1
Vincristine-induced adverse events related to body weight in dogs treated for lymphoma.长春新碱诱导的与犬淋巴瘤治疗相关的体重相关不良事件。
J Vet Intern Med. 2024 May-Jun;38(3):1686-1692. doi: 10.1111/jvim.17063. Epub 2024 Apr 2.
2
Neutropenia in dogs receiving vincristine for treatment of presumptive immune-mediated thrombocytopenia.犬接受长春新碱治疗疑似免疫介导性血小板减少症时发生中性粒细胞减少症。
J Vet Intern Med. 2021 Jan;35(1):226-233. doi: 10.1111/jvim.16029. Epub 2021 Jan 9.
3
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.
癌症治疗中的脂质基药物递送系统:现状与未来展望
Pharmacol Rev. 2016 Jul;68(3):701-87. doi: 10.1124/pr.115.012070.
4
Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT).硫酸长春新碱在患有传染性性病肿瘤(TVT)犬中的临床药代动力学及效应
J Vet Med Sci. 2014 Dec;76(12):1549-53. doi: 10.1292/jvms.14-0180. Epub 2014 Aug 21.
5
P-glycoprotein mediated drug interactions in animals and humans with cancer.P-糖蛋白介导的动物和癌症患者中的药物相互作用。
J Vet Intern Med. 2015 Jan;29(1):1-6. doi: 10.1111/jvim.12525.
6
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.玛尔奎伯(硫酸长春新碱脂质体注射液)改善了长春新碱的药代动力学和药效学。
Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64. doi: 10.1007/s00280-012-2042-4. Epub 2012 Dec 5.
7
Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells.双膦酸盐可显著提高多柔比星或长春新碱对犬恶性组织细胞瘤细胞的活性。
Vet Comp Oncol. 2012 Mar;10(1):44-56. doi: 10.1111/j.1476-5829.2011.00274.x. Epub 2011 May 18.
8
Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.饮食诱导的肥胖改变了小鼠血液和组织中长春新碱的药代动力学。
Pharmacol Res. 2010 May;61(5):385-90. doi: 10.1016/j.phrs.2010.01.007. Epub 2010 Jan 18.
9
Pharmacokinetic considerations in the treatment of CNS tumours.中枢神经系统肿瘤治疗中的药代动力学考量
Clin Pharmacokinet. 2006;45(9):871-903. doi: 10.2165/00003088-200645090-00002.
10
Penetration of intra-arterially administered vincristine in experimental brain tumor.动脉内注射长春新碱在实验性脑肿瘤中的渗透情况。
Neuro Oncol. 2004 Oct;6(4):300-5. doi: 10.1215/S1152851703000516.